Skip to content
Synopulse
  • The Brief
    • Quick
    • In Depth
    • Editor’s Pick
    • Findings
  • Reports
    • The beats
      • Catalyst
      • AccessWatch
      • DealPulse Signal
      • DealPulse Report
    • Analysis
      • The Throughline
      • The Top Line
      • The Forecast
    • Coverage
      • ShowFloor
      • The Arena
  • The Pulse
    • NeuroPulse
    • OrphanPulse
  • Topics
    • By subject
      • Deals
      • Regulatory
      • Market Access
      • Pricing & Reimbursement
      • Legal & Policy
    • By technology
      • Antibody
      • Cell & Gene Tx
      • Drug conjugates
      • AI/ML
      • Digital Health
      • Radiopharma
    • By therapy area
      • Neurology
      • Oncology
      • Rare Diseases
      • Cardio-Metabolic
      • Immunology & Inflammation
      • Orthopaedics
A Third Centiloid Scale Just Cleared. The First Two Already Disagree at the Threshold.
A Third Centiloid Scale Just Cleared. The First Two Already Disagree at the Threshold.
Athithi Verma August 19, 2026
Cortechs.ai clears NeuroQuant PET for Centiloid amyloid quantification, entering a field where the two incumbent scales differ by more than 10 Centiloids.
OrphanPulse Wk 33: The Competitor Got a PDUFA Date Five Days Later
OrphanPulse Wk 33: The Competitor Got a PDUFA Date Five Days Later
NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard
NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard
ViGNet Reported 82.55% Discrimination Predicting Immunotherapy Response in NSCLC
ViGNet Reported 82.55% Discrimination Predicting Immunotherapy Response in NSCLC
Payers Do Not Cover Wellness. In Women's Health, That Is a Naming Decision.
Payers Do Not Cover Wellness. In Women’s Health, That Is a Naming Decision.
The FDA Approved a Device and a Sentence. The Sentence Is About Other Molecules.
The FDA Approved a Device and a Sentence. The Sentence Is About Other Molecules.

Editor’s Pick

In Japan, Expanding a Label Is What Triggers the Price Cut

In Japan, Expanding a Label Is What Triggers the Price Cut

AstraZeneca Announced Nothing. The Market Charged It $24bn Anyway.

AstraZeneca Announced Nothing. The Market Charged It $24bn Anyway.

Congress Exempted the Medically Frail. The Coding System Cannot Find Them.

Congress Exempted the Medically Frail. The Coding System Cannot Find Them.

NeuroPulse


NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard

NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard

NeuroPulse Wk 32: Takeda Fixed the Cause, and Cannot Ship It Yet

NeuroPulse Wk 32: Takeda Fixed the Cause, and Cannot Ship It Yet

OrphanPulse


OrphanPulse Wk 33: The Competitor Got a PDUFA Date Five Days Later

OrphanPulse Wk 33: The Competitor Got a PDUFA Date Five Days Later

OrphanPulse Wk 32: Tarsus Paid $450M Upfront for a Readout in 2029

OrphanPulse Wk 32: Tarsus Paid $450M Upfront for a Readout in 2029

DealPulse Signal


DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Report


DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealFlow H1 2026 M&A Doubles as Upfront Spending Hits $174B

DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174B

The Beats


DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

Analysis


Reshaping Pharma by 2027

7 Market Access Trends Reshaping Pharmaย by 2027

The Biologics Patent Cliff: Inside Pharma's 2026-2029 Reckoning

The Biologics Patent Cliff: Inside Pharma’s 2026-2029 Reckoning

Coverage


The ADC Decade Accelerates What to Watch at ASCO 2026

The ADC Decade Accelerates: What to Watch at ASCO 2026

The Briefs

A Third Centiloid Scale Just Cleared. The First Two Already Disagree at the Threshold.

A Third Centiloid Scale Just Cleared. The First Two Already Disagree at the Threshold.

Athithi Verma August 19, 2026
ViGNet Reported 82.55% Discrimination Predicting Immunotherapy Response in NSCLC

ViGNet Reported 82.55% Discrimination Predicting Immunotherapy Response in NSCLC

Athithi Verma August 18, 2026
Payers Do Not Cover Wellness. In Women's Health, That Is a Naming Decision.

Payers Do Not Cover Wellness. In Women’s Health, That Is a Naming Decision.

Athithi Verma August 18, 2026
The FDA Approved a Device and a Sentence. The Sentence Is About Other Molecules.

The FDA Approved a Device and a Sentence. The Sentence Is About Other Molecules.

Admin August 18, 2026
One Missed, One Published the Arm That Failed, One Disclosed a Verb

One Missed, One Published the Arm That Failed, One Disclosed a Verb

Admin August 18, 2026
Two TROP2 Conjugates Reached the Same Patients Ten Weeks Apart, and Payers Finally Have a Choice to Make

Two TROP2 Conjugates Reached the Same Patients Ten Weeks Apart, and Payers Finally Have a Choice to Make

Athithi Verma August 14, 2026
Read More
Synopulse
Contact Us

Explore Synopulse

  • NeuroPulse
  • Deals
  • Market Access
  • Industry Trends
  • Regulatory

About

  • About Synopulse
  • Contact Us
  • Announcements
© 2026 Synopulse • Built with GeneratePress